Equillium Inc - Asset Resilience Ratio
Equillium Inc (EQ) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See EQ working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Equillium Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Equillium Inc asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Equillium Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Equillium Inc for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Equillium Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Equillium Inc Industry Peers by Asset Resilience Ratio
Compare Equillium Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Equillium Inc (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Equillium Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 17.54% | $4.49 Million | $25.60 Million | -17.39pp |
| 2023-12-31 | 34.93% | $17.65 Million | $50.53 Million | +19.73pp |
| 2022-12-31 | 15.19% | $11.92 Million | $78.42 Million | -20.34pp |
| 2021-12-31 | 35.53% | $30.34 Million | $85.41 Million | -32.57pp |
| 2020-12-31 | 68.11% | $58.18 Million | $85.43 Million | -3.78pp |
| 2019-12-31 | 71.88% | $39.92 Million | $55.54 Million | +16.19pp |
| 2018-12-31 | 55.69% | $37.40 Million | $67.16 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $7.15 Million | -- |
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as we… Read more